Eli Lilly to delay resuming U.K. investments, FT reports

Eli Lilly (LLY) will delay resuming U.K. investments until it observes changes in drug approvals, despite a recent U.S.-U.K. agreement to raise NHS drug spending and ease approval for costly medicines, The Financial Times’ Anna Gross and Aanu Adeoye report. CEO David Ricks described the company as “optimistically watching and waiting” to see how the policy shifts play out in practice. “There’s no change today in our business environment, therefore we’ve not made a change in those decisions we’ve paused,” Ricks said. “Hopefully we can observe change quickly, both in drug approval and in rollout.”